Immune Function and Vaccination After Pediatric Cancer Therapy
This study is for children and young adults aged 2 to 21 who have completed cancer treatment. It aims to understand how cancer therapy affects their immune system and their ability to fight infections. Researchers will evaluate immune function and vaccine protection over 2 years. If your child's vaccine protection is low, they will either receive booster vaccines or a full series of revaccinations (like those given after a stem cell transplant) using vaccines for diseases like Haemophilus influenza type B, tetanus, polio, and measles. The study will compare these two approaches to see which is better at restoring immunity. The goal is to improve protection against serious infections in pediatric cancer survivors.
- Study design
- This is a randomized study planning to enroll 64 participants. It will compare two different vaccination strategies.
- What's involved
- Participants will have lab evaluations for immune function at baseline, 3, 6, 9, and 24 months after finishing cancer treatment. Some participants will receive booster vaccines or a full revaccination series.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 2 years to assess vaccine protection.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ashley Hinson, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Vaccination comparison via objective lab measurements of vaccine titers2 years
To compare single booster vaccination (Arm A) to full revaccination (Arm B) in terms of immune response at 24 months post cancer directed systemic therapy in pediatric subjects who have received cancer directed systemic therapy for any malignancy.